113 related articles for article (PubMed ID: 10866141)
1. Study of synthesis and cardiovascular activity of some furoxan derivatives as potential NO-donors.
Mu L; Feng SS; Go ML
Chem Pharm Bull (Tokyo); 2000 Jun; 48(6):808-16. PubMed ID: 10866141
[TBL] [Abstract][Full Text] [Related]
2. Nicorandil analogues containing NO-donor furoxans and related furazans.
Boschi D; Cena C; Di Stilo A; Fruttero R; Gasco A
Bioorg Med Chem; 2000 Jul; 8(7):1727-32. PubMed ID: 10976520
[TBL] [Abstract][Full Text] [Related]
3. New 1,4-dihydropyridines conjugated to furoxanyl moieties, endowed with both nitric oxide-like and calcium channel antagonist vasodilator activities.
Di Stilo A; Visentin S; Cena C; Gasco AM; Ermondi G; Gasco A
J Med Chem; 1998 Dec; 41(27):5393-401. PubMed ID: 9876109
[TBL] [Abstract][Full Text] [Related]
4. Nitric oxide donor beta2-agonists: furoxan derivatives containing the fenoterol moiety and related furazans.
Buonsanti MF; Bertinaria M; Stilo AD; Cena C; Fruttero R; Gasco A
J Med Chem; 2007 Oct; 50(20):5003-11. PubMed ID: 17845020
[TBL] [Abstract][Full Text] [Related]
5. Second generation of alpha-tocopherol analogs-nitric oxide donors: Synthesis, physicochemical, and biological characterization.
López GV; Blanco F; Hernández P; Ferreira A; Piro OE; Batthyány C; González M; Rubbo H; Cerecetto H
Bioorg Med Chem; 2007 Sep; 15(18):6262-72. PubMed ID: 17627828
[TBL] [Abstract][Full Text] [Related]
6. Antitumor platinum(II) complexes containing platinum-based moieties of present platinum drugs and furoxan groups as nitric oxide donors: synthesis, DNA interaction, and cytotoxicity.
Zhao J; Gou S; Sun Y; Fang L; Wang Z
Inorg Chem; 2012 Oct; 51(19):10317-24. PubMed ID: 22957695
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of 3,4-diphenyl-1,2,5-oxadiazole-2-oxides and 3,4-diphenyl-1,2,5-oxadiazoles as potential hybrid COX-2 inhibitor/nitric oxide donor agents.
Velázquez C; Rao PN; McDonald R; Knaus EE
Bioorg Med Chem; 2005 Apr; 13(8):2749-57. PubMed ID: 15781386
[TBL] [Abstract][Full Text] [Related]
8. The excitation-contraction coupling on C2C12 skeletal muscle myotubes was modulated by NO-donor ester of gemfibrozil.
Maccallini C; Pietrangelo T; Mancinelli R; Amoroso R; Bettoni G; Fulle S
Nitric Oxide; 2008 May; 18(3):168-75. PubMed ID: 18177746
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and in vitro NO-releasing activities of ocotillol-type furoxans.
Bi Y; Yang J; Ma C; Liu ZY; Zhang TT; Zhang XC; Lu J; Meng QG
Pharmazie; 2015 Apr; 70(4):213-8. PubMed ID: 26012249
[TBL] [Abstract][Full Text] [Related]
10. NO-donor phenols: a new class of products endowed with antioxidant and vasodilator properties.
Boschi D; Tron GC; Lazzarato L; Chegaev K; Cena C; Di Stilo A; Giorgis M; Bertinaria M; Fruttero R; Gasco A
J Med Chem; 2006 May; 49(10):2886-97. PubMed ID: 16686532
[TBL] [Abstract][Full Text] [Related]
11. Syntheses, calcium channel agonist-antagonist modulation activities, and nitric oxide release studies of nitrooxyalkyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2,1,3-benzoxadiazol-4-yl)pyridine-5-carboxylate racemates, enantiomers, and diastereomers.
Shan R; Velazquez C; Knaus EE
J Med Chem; 2004 Jan; 47(1):254-61. PubMed ID: 14695839
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms. part II: furoxan derivatives.
Dos Santos JL; Lanaro C; Chelucci RC; Gambero S; Bosquesi PL; Reis JS; Lima LM; Cerecetto H; González M; Costa FF; Chung MC
J Med Chem; 2012 Sep; 55(17):7583-92. PubMed ID: 22889416
[TBL] [Abstract][Full Text] [Related]
13. The furoxan system: design of selective nitric oxide (NO) donor inhibitors of COX-2 endowed with anti-aggregatory and vasodilating activities.
Del Grosso E; Boschi D; Lazzarato L; Cena C; Di Stilo A; Fruttero R; Moro S; Gasco A
Chem Biodivers; 2005 Jul; 2(7):886-900. PubMed ID: 17193179
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis.
Fernandes GFDS; de Souza PC; Marino LB; Chegaev K; Guglielmo S; Lazzarato L; Fruttero R; Chung MC; Pavan FR; Dos Santos JL
Eur J Med Chem; 2016 Nov; 123():523-531. PubMed ID: 27508879
[TBL] [Abstract][Full Text] [Related]
15. A new class of ibuprofen derivatives with reduced gastrotoxicity.
Lolli ML; Cena C; Medana C; Lazzarato L; Morini G; Coruzzi G; Manarini S; Fruttero R; Gasco A
J Med Chem; 2001 Oct; 44(21):3463-8. PubMed ID: 11585451
[TBL] [Abstract][Full Text] [Related]
16. A new class of furoxan derivatives as NO donors: mechanism of action and biological activity.
Ferioli R; Folco GC; Ferretti C; Gasco AM; Medana C; Fruttero R; Civelli M; Gasco A
Br J Pharmacol; 1995 Feb; 114(4):816-20. PubMed ID: 7773542
[TBL] [Abstract][Full Text] [Related]
17. Schiff bases containing a furoxan moiety as potential nitric oxide donors in plant tissues.
Georgescu E; Oancea A; Georgescu F; Nicolescu A; Oprita EI; Vladulescu L; Vladulescu MC; Oancea F; Shova S; Deleanu C
PLoS One; 2018; 13(7):e0198121. PubMed ID: 29990316
[TBL] [Abstract][Full Text] [Related]
18. Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
Ling Y; Ye X; Zhang Z; Zhang Y; Lai Y; Ji H; Peng S; Tian J
J Med Chem; 2011 May; 54(9):3251-9. PubMed ID: 21504204
[TBL] [Abstract][Full Text] [Related]
19. New potential uroselective NO-donor alpha1-antagonists.
Boschi D; Tron GC; Di Stilo A; Fruttero R; Gasco A; Poggesi E; Motta G; Leonardi A
J Med Chem; 2003 Aug; 46(17):3762-5. PubMed ID: 12904082
[TBL] [Abstract][Full Text] [Related]
20. Molecular Hybridization Tools in the Development of Furoxan-Based NO-Donor Prodrugs.
Fershtat LL; Makhova NN
ChemMedChem; 2017 May; 12(9):622-638. PubMed ID: 28371340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
